BioSpace News Archive

Aesther Healthcare Acquisition Corp, a special purpose acquisition company has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a next-generation biopharma company.

Genprex, Inc. announced that its Chief Financial Officer, Ryan Confer, will be providing a virtual overview of the Company’s gene therapies for cancer and diabetes at the following investor conference in September 2022.

New detailed results from Eli Lilly and Company’s (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients who achieved a clinical response* at Week 16 through one year of treatment.

Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, at the 31st European Academy of Dermatology and Venereology (EADV) Congress, taking place in Milan, Italy, Sept. 7-10, 2022.

Biofidelity, a revolutionary genomic technology company dedicated to unleashing the potential of genomics to transform human health and the world we live in, announced the issuance of several new patents in the US, Europe, and China.

Cardiff Oncology, Inc. announced that company management will present and participate in 1x1 investor meetings at the Baird Global Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference taking place in New York, NY, on September 13 – 14, 2022, and September 12 – 14, 2022, respectively.

LEO Pharma A/S, a global leader in medical dermatology, today announced new safety data for AdbryTM (tralokinumab-ldrm) for adult patients with moderate-to-severe atopic dermatitis (AD).

Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced a new distribution agreement with Proteigene

Lunaphore and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies.

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, announced that senior management will present a company overview at two upcoming investor conferences.